Hypothermia: Is it Good for the Brain and Not for the Arteries?  by Conti, C. Richard
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We thank Drs. Guazzi and Bandera for their thoughtful com-
ments in which they assert the value of incorporating multiple
variables from cardiopulmonary exercise (CPX) testing to best
reflect the complex pathophysiology of chronic heart failure (HF)
and thereby maximize its prognostic value. We agree with this
concept, and even made a similar point in our paper, “Oscillatory
expiratory breathing, end-tidal partial pressure of carbon dioxide,
VE/VO2 ratios, recovery gas exchange dynamics, and heart rate
nd blood pressure responses are among an extensive array of CPX
ssessments that can be used to enhance prognostic assessment”
1). Unfortunately, these additional gas exchange variables were
ot collected as part of the HF-ACTION (Heart Failure–A
andomized Controlled Trial Investigating Outcomes of Exercise
raining) trial database.
Drs. Guazzi and Bandera also state that EOV has been “proven
rognostically superior” to both peak VO2 and VE/VCO2 slope as
ell as the 6MWT. However, this assertion seems primarily based
pon their single center study of 253 patients, which included both
eart failure with reduced ejection fraction (HFrEF) and heart
ailure with preserved ejection fraction (HFpEF) subgroups (2).
n contrast, HF-ACTION included 2,054 patients from over
0 sites, all with HFrEF, and with a much larger number of
vents. Furthermore, the 6MWT protocol used in Guazzi’s
eference was based on stride length and number of steps taken
which assumed that stride length did not change as patients
atigued), which is considerably different from the standardized
nd validated 6MWT protocol used in HF-ACTION (1).
hese differences likely account for the better prognostic
erformance of the 6MWT in HF-ACTION.
Measurement of EOV relies on variations of minute ventilation
ver time, which are usually assessed qualitatively from graphs,
ith inherent ambiguity regarding classification amidst normal
uctuations associated with breath-to-breath ventilation during
xercise. In contrast, 6MW distance is a simple measure that can
e readily incorporated into clinical practice and trials without
pecialized equipment, and which is reproducible as long as a
tandardized test protocol is used.
To summarize, we agree with Drs. Guazzi and Bandera
egarding the undisputed utility of CPX for providing pathophys-
ological insights and prognostic assessments in patients with HF,
nd also for its multiple unique diagnostic applications. However,
ur analysis indicates that the 6MWT also has significant value,
oth in respect to prognostic sensitivity as well as its relative
onvenience.
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Hypothermia: Is it Good for the
Brain and Not for the Arteries?
I read with interest the research correspondence letter by Penela et
al. (1). As pointed out by the authors, the protocol for induced
hypothermia is designed to reduce the temperature of the patient
to 32°C to 34°C for up to 24 h. The results of this form of therapy
are summarized in the Annals of Neurology (2). Up to two-thirds of
patients receiving hypothermia therapy might go home with good
function, but recovery of higher intellectual faculties has not been
well-studied, and nothing is reported about the effects of hypo-
thermia on atherosclerotic vessels in these patients.
As far as I can tell, no one has considered what the effects of
induced hypothermia are on atherosclerotic lesions either in the
cerebral or coronary circulation.
Several years ago, Vedre et al. (3) reported that local factors
might play an important role in triggering plaque rupture. One of
these factors was temperature. They showed that cholesterol
crystallizes from a liquid to a solid form and forms sharp-tipped
crystals that expand in volume by up to 45%. In vitro experiments
documented that there was a significant difference in the change of
volume expansion of cholesterol between 34°C and 37°C.
In the human, it is theoretically possible that crystallization of
cholesterol at low temperatures at approximately 34°C might be
sufficient to trigger cholesterol crystallization, especially in combi-
nation with other physical factors. Because all of these patients very
likely have atherosclerotic plaques in the coronary circulation and
perhaps the cerebral circulation as well, rupture of atherosclerotic
plaques might be triggered by the formation of sharp-tipped
cholesterol crystals. Thus, it is possible that cooling the patient to
34°C or less could potentially worsen the vascular stenoses by
sharp-crystallized cholesterol disrupting plaques or, as the authors
point out, “activation of platelets” might be responsible for throm-
bosis despite treating with clopidogrel (because hypothermia might
decrease metabolism of cholesterol to its active form). Thus, it is
important to consider the possibility that lowering temperature to
prevent brain ischemia or brain infarction might in fact be
detrimental to coronary and cerebral vessels, both from the
standpoint of disrupting plaques and thrombosis occurring in
patients with stents.
Hypothermia might buttress the clinical evidence that myocar-
dial infarction and unstable angina syndromes occur more fre-
quently in cold weather and during early morning hours when
body temperature is slightly lower in most patients. Interestingly,
platelet activation apparently occurs in the morning hours as well.
I certainly agree that the evidence favors lowering body tem-
perature to diminish ischemic brain damage, but it is possible, on
the basis of the work of Vedre et al. (3) and Penela et al. (1), that
R2114 Correspondence JACC Vol. 61, No. 20, 2013
May 21, 2013:2110–4cooling the patient to 34°C might do something detrimental to the
vasculature.
I share the concern of the authors that these observations
require further study, because hypothermia might result in untow-
ard effects not perceived by the early proponents of this therapy.
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